A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
暂无分享,去创建一个
J. Nutt | C. Adler | L. Josephson | C. Tanner | A. Lang | R. Pahwa | M. Aminoff | S. Fahn | J. Hubble | A. Siderowf | K. Kieburtz | K. Blindauer | S. Plumb | I. Shoulson | M. Stacy | W. Ondo | K. Shannon | K. Marek | R. Hauser | C. Hunter | M. Stern | Cathi A Thomas | W. White | J. Richman | A. Feigin | P. Tuite | A. Rajput | W. Martin | L. Golbe | K. Sethi | R. Feldman | E. Molho | C. Cox | R. Levy | H. Hurtig | U. Kang | M. Gordon | D. Oakes | F. Marshall | L. Shulman | S. Eberly | J. Jaglin | J. Wojcieszek | J. Miyasaki | I. Gardiner | G. Dowling | P. Atchison | P. Gray | M. Klimek | K. Conn | C. Irvine | M. Lew | V. Calabrese | J. Bertoni | D. Ladkani | L. Gauger | S. Oren | A. Shinaman | M. DeAngelis | Diane L. Brown | Debra Berry | S. Daigneault | S. Schwid | D. Day | E. Eyal | C. Peterson | K. Williamson | P. LeWitt | Karen Stavris | T. Mendis | G. McInnes | A. Brocht | J. Belden | Pamela King | Barbara Shannon | C. Allen | B. Ebbitt | J. Bausch | C. Chadwick | Neila Mendis | M. Lloyd | Luisa Del Rizzo | Karen Betcher | Marianne Ewanishin | M. Diminno | M. Schear | Roberta Winnick | Jeannette Connolly | R. Oliva | W. Houck | Kelli Williamson
[1] Michael P McDermott,et al. Development and testing of the Parkinson's disease quality of life scale , 2003, Movement disorders : official journal of the Movement Disorder Society.
[2] M. Carrillo,et al. Mechanism underlying anti-apoptotic activity of a (−)deprenyl-related propargylamine, rasagiline , 2000, Mechanisms of Ageing and Development.
[3] M. Carrillo,et al. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. , 2000, Life sciences.
[4] P. Lazarovici,et al. Rasagiline, a monoamine oxidase‐B inhibitor, protects NGF‐differentiated PC12 cells against oxygen‐glucose deprivation , 1999, Journal of neuroscience research.
[5] E. Shohami,et al. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. , 1999, European journal of pharmacology.
[6] J. Friedman,et al. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease , 1997, Neurology.
[7] C. Adler,et al. Ropinirole for the treatment of early Parkinson's disease , 1997, Neurology.
[8] R Kieburtz,et al. Effect of lazabemide on the progression of disability in early Parkinson's disease , 1996, Annals of neurology.
[9] J. Jankovic,et al. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group. , 1995, Archives of neurology.
[10] K. Kieburtz. A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's disease , 1993, Annals of neurology.
[11] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[12] Y. Hochberg. A sharper Bonferroni procedure for multiple tests of significance , 1988 .
[13] R. Duvoisin,et al. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. , 1985, European journal of pharmacology.
[14] M. Youdim,et al. TYRAMINE ANTAGONISTIC PROPERTIES OF AGN 1135, AN IRREVERSIBLE INHIBITOR OF MONOAMINE OXIDASE TYPE B , 1981, British journal of pharmacology.
[15] P. Armitage,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.
[16] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[17] A. Beck,et al. An inventory for measuring depression. , 1961, Archives of general psychiatry.
[18] Z. Speiser,et al. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. , 1998, Journal of neural transmission. Supplementum.
[19] D. Goldstein,et al. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey. , 1998, Journal of neural transmission. Supplementum.
[20] R. Levy,et al. (R)(+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. , 1998, Journal of neural transmission. Supplementum.
[21] M. Brin,et al. A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group. , 1994, Archives of neurology.
[22] D. Brooks,et al. Core assessment program for intracerebral transplantations (CAPIT) , 1992, Movement disorders : official journal of the Movement Disorder Society.
[23] Anthony E. Lang,et al. Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.